These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 11220521

  • 1. Mechanisms of action of class III agents and their clinical relevance.
    Dorian P.
    Europace; 2000 Jul; 1 Suppl C():C6-9. PubMed ID: 11220521
    [Abstract] [Full Text] [Related]

  • 2. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR, Uchida AH, Ferreira C, Ferreira Filho C, Schapachnik E, Dubner S, Zhang L, Moffa PJ.
    Cardiol J; 2008 Jul; 15(3):209-19. PubMed ID: 18651412
    [Abstract] [Full Text] [Related]

  • 3. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P, Tegelkamp R, Osada N, Schimpf R, Wolpert C, Breithardt G, Borggrefe M, Eckardt L.
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [Abstract] [Full Text] [Related]

  • 4. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J.
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [Abstract] [Full Text] [Related]

  • 5. Basic cardiac electrophysiology and mechanisms of antiarrhythmic agents.
    Perry RS, Illsley SS.
    Am J Hosp Pharm; 1986 Apr; 43(4):957-74. PubMed ID: 2871752
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New antiarrhythmic agents for atrial fibrillation and atrial flutter.
    Pecini R, Elming H, Pedersen OD, Torp-Pedersen C.
    Expert Opin Emerg Drugs; 2005 May; 10(2):311-22. PubMed ID: 15934869
    [Abstract] [Full Text] [Related]

  • 8. Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part I: Molecular and ionic fundamentals of antiarrhythmic drug actions.
    Calò L, Sciarra L, Lamberti F, Loricchio ML, Castro A, Bianconi L, Pandozi C, Gaita F, Santini M.
    Ital Heart J; 2003 Jul; 4(7):430-41. PubMed ID: 14558293
    [Abstract] [Full Text] [Related]

  • 9. New perspectives in cardiology: pharmacodynamic classification of antiarrhythmic drugs.
    Adams HR.
    J Am Vet Med Assoc; 1986 Sep 01; 189(5):525-32. PubMed ID: 2875984
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Current and new drugs for the treatment of arrhythmias.
    Auer J, Berent R, Weber T, Lassnig E, Eber B.
    Curr Opin Investig Drugs; 2002 Jul 01; 3(7):1029-36. PubMed ID: 12186263
    [Abstract] [Full Text] [Related]

  • 12. [Inhibition of the muscarinic potassium current by KB130015, a new antiarrhythmic agent to treat atrial fibrillation].
    Borchard R, van Bracht M, Wickenbrock I, Prull MW, Pott L, Trappe HJ.
    Med Klin (Munich); 2005 Nov 15; 100(11):697-703. PubMed ID: 16328176
    [Abstract] [Full Text] [Related]

  • 13. Hybrid therapy of atrial fibrillation.
    Santini M, Pignalberi C, Ricci R, Calò L.
    Ital Heart J; 2002 Oct 15; 3(10):571-8. PubMed ID: 12478814
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A, Starmer CF, Bezerianos A.
    IEEE Trans Biomed Eng; 2003 Feb 15; 50(2):168-77. PubMed ID: 12665030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.